Peptides explained
Ipamorelin: how it works
Page updated · Sources and editorial approach
Ipamorelin activates the ghrelin receptor. Learn about growth-hormone signalling, gastrointestinal research and what a negative phase 2 endpoint means.
Ipamorelin at a glance
What it does biologically
It is a ghrelin-receptor agonist, associated with growth-hormone release and gastrointestinal signalling.
What the evidence shows
A phase 2 postoperative study tested tolerance of a solid meal; the primary comparison did not reach statistical significance.
What remains uncertain
This does not establish benefits for muscle growth, sleep, general recovery or combinations with CJC-related peptides.
The basics
What is Ipamorelin?
Ipamorelin is a synthetic peptide agonist of the ghrelin receptor. Ghrelin biology includes growth-hormone release and effects on gastrointestinal function. A receptor name describes pharmacology rather than an approved wellness use.
Ipamorelin is often discussed alongside GHRH analogues, but the receptor systems are different. A combination is a new intervention and needs direct evidence.
Biological action
How does Ipamorelin work?
Activating the ghrelin receptor can influence hormone release and gut motility. The importance of either response depends on tissue, exposure and the condition being studied.
In a randomised postoperative ileus study, the main efficacy question was how soon patients tolerated a standardised solid meal after bowel surgery. It was not a trial of exercise performance, anti-ageing or a CJC/ipamorelin blend.
Questions being investigated
What do studies examine?
Gastrointestinal motility
The phase 2 trial examined recovery of meal tolerance after abdominal surgery.
Growth-hormone signalling
Ghrelin-receptor activation is distinct from GHRH-receptor stimulation.
Outcome interpretation
A numerical difference without a statistically significant primary result should not be described as proven efficacy.
Strength of evidence
How strong is the evidence?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
| Evidence type | What it tells us |
|---|---|
| Laboratory | Receptor pharmacology supports a ghrelin-mimetic mechanism. |
| Animal | Preclinical gut effects informed clinical investigation. |
| Human | The phase 2 surgical trial enrolled 117 people; its main efficacy comparison was not statistically significant. |
| Regulatory | A proof-of-concept study does not establish an authorised indication or a general wellness benefit. |
Important context
Risks, limitations and unanswered questions
- A postoperative hospital population differs from healthy consumers.
- The primary meal-tolerance comparison had p=0.15 and did not establish efficacy.
- Short follow-up does not settle long-term endocrine effects.
- A study of ipamorelin alone does not establish a blend's benefit or safety.
Reading the original evidence
Read the primary result, including uncertainty
The postoperative ileus trial examined tolerance of a solid meal after bowel surgery. The reported difference in the key endpoint was not statistically significant. The study should not be reframed as proof of a general recovery benefit or an athletic outcome.
Question to take to the source: Was the prespecified endpoint supported, and is the surgical setting preserved when the finding is described?
Check the original source ↗For personal accounts and research questionnaires, read user feedback and patient-reported outcomes.
Questions answered
Ipamorelin FAQs
Does ipamorelin work through the same receptor as CJC-1295?
No. Ipamorelin acts at the ghrelin receptor; CJC-1295 is a GHRH analogue.
Did the surgical trial prove it works?
No. The primary efficacy comparison was not statistically significant.
Does hormone release prove recovery benefits?
No. Direct studies of meaningful recovery outcomes are needed.
Check the sources
Sources and further reading
Follow the original study or official information to check the population, methods and full results. Reviews and sponsor updates are labelled below.
- Beck et al. (2014): postoperative ileus trial ↗Primary randomised, double-blind, placebo-controlled phase 2 study.
- Study registration NCT00672074 ↗Official trial record for the postoperative programme.
Educational information, prepared with AI assistance and not independently clinically reviewed. It is not personal medical advice or a treatment recommendation. Read the editorial policy or suggest a correction.